Neuroprotection in metabolism-based therapy

Adam L. Hartman

Research output: Contribution to journalArticle

Abstract

Metabolism-based therapy has been used successfully in the treatment of seizures but study of its use in other neurodegenerative disorders is growing. Data demonstrating the use of different forms of metabolism-based therapy in human trials of Alzheimer disease and Parkinson disease are discussed. Animal and in vitro studies have shed light on metabolism-based therapy's mechanisms in these diseases, as well as ALS, aging, ischemia, trauma and mitochondrial cytopathies. Additional insights may be obtained by considering the role of metabolism-based therapy in cell disability and death (specifically apoptosis, excitotoxicity, and autophagy).

Original languageEnglish (US)
Pages (from-to)286-294
Number of pages9
JournalEpilepsy Research
Volume100
Issue number3
DOIs
StatePublished - Jul 2012

Fingerprint

Autophagy
Therapeutics
Neurodegenerative Diseases
Parkinson Disease
Alzheimer Disease
Seizures
Cell Death
Ischemia
Apoptosis
Neuroprotection
Wounds and Injuries
In Vitro Techniques
Mitochondrial cytopathy

Keywords

  • Alzheimer disease
  • Calorie restriction
  • Epilepsy
  • Ketogenic diet
  • Neuroprotection
  • Parkinson disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Neuroprotection in metabolism-based therapy. / Hartman, Adam L.

In: Epilepsy Research, Vol. 100, No. 3, 07.2012, p. 286-294.

Research output: Contribution to journalArticle

Hartman, Adam L. / Neuroprotection in metabolism-based therapy. In: Epilepsy Research. 2012 ; Vol. 100, No. 3. pp. 286-294.
@article{47b01e66228146d5a2befaf4ae92967b,
title = "Neuroprotection in metabolism-based therapy",
abstract = "Metabolism-based therapy has been used successfully in the treatment of seizures but study of its use in other neurodegenerative disorders is growing. Data demonstrating the use of different forms of metabolism-based therapy in human trials of Alzheimer disease and Parkinson disease are discussed. Animal and in vitro studies have shed light on metabolism-based therapy's mechanisms in these diseases, as well as ALS, aging, ischemia, trauma and mitochondrial cytopathies. Additional insights may be obtained by considering the role of metabolism-based therapy in cell disability and death (specifically apoptosis, excitotoxicity, and autophagy).",
keywords = "Alzheimer disease, Calorie restriction, Epilepsy, Ketogenic diet, Neuroprotection, Parkinson disease",
author = "Hartman, {Adam L.}",
year = "2012",
month = "7",
doi = "10.1016/j.eplepsyres.2011.04.016",
language = "English (US)",
volume = "100",
pages = "286--294",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Neuroprotection in metabolism-based therapy

AU - Hartman, Adam L.

PY - 2012/7

Y1 - 2012/7

N2 - Metabolism-based therapy has been used successfully in the treatment of seizures but study of its use in other neurodegenerative disorders is growing. Data demonstrating the use of different forms of metabolism-based therapy in human trials of Alzheimer disease and Parkinson disease are discussed. Animal and in vitro studies have shed light on metabolism-based therapy's mechanisms in these diseases, as well as ALS, aging, ischemia, trauma and mitochondrial cytopathies. Additional insights may be obtained by considering the role of metabolism-based therapy in cell disability and death (specifically apoptosis, excitotoxicity, and autophagy).

AB - Metabolism-based therapy has been used successfully in the treatment of seizures but study of its use in other neurodegenerative disorders is growing. Data demonstrating the use of different forms of metabolism-based therapy in human trials of Alzheimer disease and Parkinson disease are discussed. Animal and in vitro studies have shed light on metabolism-based therapy's mechanisms in these diseases, as well as ALS, aging, ischemia, trauma and mitochondrial cytopathies. Additional insights may be obtained by considering the role of metabolism-based therapy in cell disability and death (specifically apoptosis, excitotoxicity, and autophagy).

KW - Alzheimer disease

KW - Calorie restriction

KW - Epilepsy

KW - Ketogenic diet

KW - Neuroprotection

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=84864080763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864080763&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2011.04.016

DO - 10.1016/j.eplepsyres.2011.04.016

M3 - Article

C2 - 21872441

AN - SCOPUS:84864080763

VL - 100

SP - 286

EP - 294

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 3

ER -